Prognostic relevance of circulating CK19 mRNA in advanced malignant biliary tract diseases

Table 4 Survival analysis using clinical parameters measured by univariable and multivariable analysis

Variables	Univariable analysis		Multivariate analysis
	P value	Hazard ratio	P value	Hazard ratio
		(95% CI)		(95% CI)
CK19 expression	0.0111	2.42 (1.22-4.78)	0.0241	3.20 (1.17-8.75)
hTERT expression	0.188	1.60 (0.80-3.22)	0.580	1.34 (0.47-3.82)
Age	0.541	0.82 (0.42-1.57)	0.0261	0.38 (0.16-0.89)
Total bilirubin	0.106	1.72 (0.89-3.31)	0.0021	3.97 (1.69-9.36)
Albumin	0.360	0.73 (0.37-1.35)	0.213	0.59 (0.26-1.35)
CA19-9	0.374	0.73 (0.37-1.43)	0.478	0.74 (0.32-1.70)
CEA	0.381	1.39 (0.68-2.88)	0.124	1.86 (0.84-4.12)

¹Statistically significant. CI: Confidence interval; CK19: Cytokeratin 19; hTERT: Human telomerase reverse transcriptase; CA: Cancer antigen; CEA: Carcinoembryonic antigen.